[Effect of puerarin on fibrinolytic activity and lipid peroxide in patients with coronary heart disease].
OBJECTIVE
To observe the effect of puerarin on superoxide dismutase (SOD), lipid peroxidation (LPO), tissue plasminogen (TPA) and plasminogen activator inhibitor (PAI-1) of coronary heart disease (CHD) patients.


METHODS
Forty-eight patients were divided into two groups (treated group and control group). Treated group was given intravenously 600 mg puerarin, once daily for one week, also the same treatment as that of control was given. Nitrite colorimetric method, radioimmunoassay (RIA), TBA fluorescent development process and fibrinolysin specific colorbase substrate decomposition development process were used to determine SOD activity, SOD, LPO, TPA and PAI-1.


RESULTS
After the treatment with puerarin, SOD activity was increased, LPO reduced, while without any changes in the control group. There was insignificant changes of SOD between the treated and the control groups. TPA and PAI-1 were increased significantly in the treated group, but was insignificantly changed in the control group.


CONCLUSIONS
Puerarin can increase the SOD activity, decrease LPO level and enhance the activity of fibrinolysis.
Chen
J
J
Department of Cardiology, First Affiliated Hospital, Hubei Medical University, Wuhan (430060).
Xu
J
J
Li
J
J
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007529:Isoflavones / Q000627:therapeutic use*; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D015849:Plasminogen Inactivators / Q000378:metabolism; D013482:Superoxide Dismutase / Q000097:blood*; D010959:Tissue Plasminogen Activator / Q000378:metabolism
D000319:Adrenergic beta-Antagonists; D007529:Isoflavones; D015849:Plasminogen Inactivators; D013482:Superoxide Dismutase; D010959:Tissue Plasminogen Activator; C033607:puerarin